AstraZeneca COPD drug succeeds in late-stage trials, eyes market niche

AstraZeneca's experimental COPD treatment met primary endpoints in late-stage studies, showing efficacy that could rival existing therapies. The drug may capture a distinct market segment, though regulatory approval and commercial launch remain pending. This strengthens AstraZeneca's respiratory pipeline and competitive positioning.